We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
Moderna
MRNA
$58.1B
| $232K | ﹤0.01% |
1,953
+104
| +6% | +$13.2K |
|
1452
Graham Holdings Company
GHC
$4.81B
| $228K | ﹤0.01% |
326
-29
| -8% | -$21.2K |
|
1453
Mercantile Bank Corp
MBWM
$1.05B
| $228K | ﹤0.01% |
5,611
+823
| +17% | +$30.8K |
|
|
CUTR
1454
DELISTED
Cutera, Inc.
CUTR
| $227K | ﹤0.01% |
150,200
+1,218
| +0.8% | +$2.45K |
|
1455
Crown Castle
CCI
$31.2B
| $224K | ﹤0.01% |
2,295
-453,889
| -99% | -$44.7M |
|
1456
Kelly Services Class A
KELYA
$566M
| $224K | ﹤0.01% |
10,454
+668
| +7% | +$15.2K |
|
1457
Deckers Outdoor
DECK
$10.6B
| $224K | ﹤0.01% |
1,386
+774
| +126% | +$119K |
|
|
ALTM
1458
DELISTED
Arcadium Lithium plc
ALTM
| $223K | ﹤0.01% |
66,315
-15,794
| -19% | -$66K |
|
1459
Chemours
CC
$2.17B
| $222K | ﹤0.01% |
9,840
-7,962
| -45% | -$208K |
|
|
IAS
1460
DELISTED
Integral Ad Science
IAS
| $219K | ﹤0.01% |
+22,500
| New | +$215K |
|
|
SVCO
1461
Silvaco Group
SVCO
$220M
| $216K | ﹤0.01% |
+12,000
| New | +$218K |
|
1462
OneMain Financial
OMF
$6.97B
| $215K | ﹤0.01% |
4,427
-5,242
| -54% | -$258K |
|
1463
Warner Bros
WBD
$70.4B
| $214K | ﹤0.01% |
28,818
-352,385
| -92% | -$2.82M |
|
1464
Lumentum
LITE
$82.5B
| $214K | ﹤0.01% |
4,200
-125
| -3% | -$5.66K |
|
1465
Old Second Bancorp
OSBC
$1.27B
| $212K | ﹤0.01% |
14,339
+221
| +2% | +$3.11K |
|
1466
TriNet
TNET
$3.18B
| $210K | ﹤0.01% |
2,098
-311
| -13% | -$34.6K |
|
1467
Packaging Corp of America
PKG
$20.6B
| $209K | ﹤0.01% |
1,147
-9
| -0.8% | -$1.64K |
|
|
TXNM
1468
TXNM Energy Inc
TXNM
$6.03B
| $209K | ﹤0.01% |
5,657
-4,612
| -45% | -$172K |
|
1469
Adaptive Biotechnologies
ADPT
$4.42B
| $207K | ﹤0.01% |
57,272
-1,244,445
| -96% | -$3.95M |
|
1470
Sierra Bancorp
BSRR
$526M
| $205K | ﹤0.01% |
9,153
| – | – |
|
1471
Moody's
MCO
$80.6B
| $205K | ﹤0.01% |
486
-7
| -1% | -$2.79K |
|
1472
Leidos
LDOS
$16.2B
| $201K | ﹤0.01% |
1,381
+876
| +173% | +$122K |
|
1473
Willdan Group
WLDN
$1.19B
| $201K | ﹤0.01% |
6,979
| – | – |
|
1474
Kymera Therapeutics
KYMR
$9.67B
| $201K | ﹤0.01% |
6,727
-39
| -0.6% | -$1.35K |
|
1475
QuidelOrtho
QDEL
$739M
| $200K | ﹤0.01% |
6,018
+3,595
| +148% | +$147K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.